Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects

Gene Therapy volume 12, pages 1119–1125 (2005)Cite this article

Abstract

Gene therapy for dominant-negative disorders presents a more difficult challenge than gene therapy for recessive disorders, since even partial replacement of a protein for a recessive disorder can reverse symptoms. Osteogenesis imperfecta (OI) has frequently served as a model disorder for dominant-negative defects of structural proteins. The disease is caused by mutations in type I collagen (COL1A1), the major structural component of bone, skin and other connective tissues. The severity of the phenotype is largely dependent on the ratio of normal to mutant type I procollagen synthesized by cells. Recently, attempts have been made to develop strategies for cell and gene therapies using the adult stem cells from bone marrow referred to as mesenchymal stem cells or marrow stromal cells (MSCs). In this study, we used MSCs from a patient with type III OI who was heterozygous for an IVS 41A + 4C mutation in COL1A1. A hybrid genomic / cDNA construct of COL1A1 was transfected into the MSCs and the transfectants were expanded over a 200-fold. Transfected MSCs showed increased expression of the wild-type mRNA and protein. In vitro assays demonstrated that the transfected cells more efficiently differentiated into mineralizing cells. The results indicated that it is possible to overexpress COL1A1 cDNA in OI MSCs and thereby to correct partially the dominant-negative protein defect.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Kuivaniemi H, Tromp G, Prockop DJ . Mutations in fibrillar collagens (types I, II, III, and XI), fibril-associated collagen (type IX), and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage, and blood vessels. Hum Mutat 1997; 9: 300–315.

    Article  CAS  Google Scholar 

  2. Myllyharju J, Kivirikko KI . Collagens and collagen-related diseases. Ann Med 2001; 33: 7–21.

    Article  CAS  Google Scholar 

  3. Pereira RF et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1998; 95: 1142–1147.

    Article  CAS  Google Scholar 

  4. Horwitz EM et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227–1231.

    Article  CAS  Google Scholar 

  5. Horwitz EM et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–313.

    Article  CAS  Google Scholar 

  6. Horwitz EM et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932–8937.

    Article  CAS  Google Scholar 

  7. Koc ON et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215–222.

    Article  CAS  Google Scholar 

  8. Koc ON et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte–macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824–1830.

    Article  CAS  Google Scholar 

  9. Cabral WA et al. Procollagen with skipping of alpha 1(I) exon 41 has lower binding affinity for alpha1(I) C-telopeptide, impaired in vitro fibrillogenesis, and altered fibril morphology. J Biol Chem 2002; 277: 4215–4222.

    Article  CAS  Google Scholar 

  10. Hormuzdi SG, Penttinen R, Jaenisch R, Bornstein P . A gene-targeting approach identifies a function for the first intron in expression of the alpha1(I) collagen gene. Mol Cell Biol 1998; 18: 3368–3375.

    Article  CAS  Google Scholar 

  11. Krempen K et al. Far upstream regulatory elements enhance position-independent and uterus-specific expression of the murine alpha1(I) collagen promoter in transgenic mice. Gene Expr 1999; 8: 151–163.

    CAS  PubMed  Google Scholar 

  12. Braut A et al. COL1A1-GFP transgene expression in developing incisors. Connect Tissue Res 2002; 43: 216–219.

    Article  CAS  Google Scholar 

  13. Hernandez I et al. Collagen alpha1(I) gene contains an element responsive to tumor necrosis factor-alpha located in the 5′ untranslated region of its first exon. DNA Cell Biol 2000; 19: 341–352.

    Article  CAS  Google Scholar 

  14. Olsen AS, Geddis AE, Prockop DJ . High levels of expression of a minigene version of the human pro alpha1(I) collagen gene in stably transfected mouse fibroblasts. Effects of deleting putative regulatory sequences in the first intron. J Biol Chem 1991; 266: 1117–1121.

    CAS  PubMed  Google Scholar 

  15. Sarafova AP et al. Three novel type I collagen mutations in osteogenesis imperfecta typy IV probands are associated with discrepancies between electrophorectic migration of osteoblast and fibroblast collagen. Hum Mutat 1998; 11: 395–403.

    Article  CAS  Google Scholar 

  16. Prockop DJ, Gregory CA, Spees JL . One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 2003; 100 (Suppl 1): 11917–11923.

    Article  CAS  Google Scholar 

  17. Sokolov BP et al. Tissue-specific expression of the gene for type I procollagen (COL1A1) in transgenic mice. Only 476 base pairs of the promoter are required if collagen genes are used as reporters. J Biol Chem 1995; 270: 9622–9629.

    Article  CAS  Google Scholar 

  18. Constantinou-Deltas CD, Ladda RL, Prockop DJ . Somatic cell mosaicism: another source of phenotypic heterogeneity in nuclear families with osteogenesis imperfecta. Am J Med Genet 1993; 45: 246–251.

    Article  CAS  Google Scholar 

  19. Cabral WA, Marini JC . High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet 2004; 74: 752–760.

    Article  CAS  Google Scholar 

  20. Forlino A, Marini JC . Osteogensis imperfecta: prospects for molecular therapeutics. Mol Genet Metab 2000; 71: 225–329.

    Article  CAS  Google Scholar 

  21. Millington-Ward S et al. RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 2004; 12: 864–866.

    Article  CAS  Google Scholar 

  22. Chamberlain JR et al. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004; 303: 1198–1201.

    Article  CAS  Google Scholar 

  23. Stanford CM et al. Rapidly forming apatite mineral in an osteoblastic cell line (UMR 106-01 BSP). J Biol Chem 1995; 270: 9420–9428.

    Article  CAS  Google Scholar 

  24. Hojima Y, van der Rest M, Prockop DJ . Type I procollagen carboxyl-terminal proteinase from chick embryos. Purification and characterization. J Biol Chem 1985; 260: 15996–16003.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The work was supported in part by grants from NIH (AR-48323), HCA the Healthcare Company, the Oberkotter Foundation, and the Louisiana Gene Therapy Research Consortium to DJP and NIH / NIAMS fellowship to RRP.

Author information

Authors and Affiliations

  1. Center for Gene Therapy, Tulane University Health Sciences Center, New Orleans, LA, USA

    R R Pochampally & D J Prockop

  2. Division of Stem Cell Transplantation and Experimental Hematology, St Jude Children's Research Hospital, Memphis, TN, USA

    E M Horwitz

  3. Women & Infants Hospital of Rhode Island, Providence, RI, USA

    C M DiGirolamo

  4. Thomas Jefferson University, Philadelphia, PA, USA

    D S Stokes

Authors
  1. R R Pochampally
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E M Horwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C M DiGirolamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D S Stokes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D J Prockop
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pochampally, R., Horwitz, E., DiGirolamo, C. et al. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Gene Ther 12, 1119–1125 (2005). https://doi.org/10.1038/sj.gt.3302514

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302514

Keywords

This article is cited by

Search

Advanced search

Quick links